12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Arikace: FDA hold

Insmed said in its 4Q11 earnings that it submitted a complete response to FDA's requests regarding a clinical hold on Arikace in CF patients, but did not disclose details. Last August, FDA placed a clinical hold on 2 planned trials of Arikace in patients with CF and in patients with non-tuberculosis mycobacteria (NTM) lung infection following undisclosed interim data...

Read the full 272 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >